Fenugreek Compound (N55) Lowers Plasma Glucose through the Enhancement of Response of Physiological Glucagon-like peptide-1
نویسندگان
چکیده
منابع مشابه
Glucagon-like Peptide-1 Improves Glucose Tolerance
Wistar rats develop glucose intolerance and have a diminished insulin response to glucose with age. The aim of this study was to investigate if these changes were reversible with glucagon-like peptide-1 (GLP-1), a peptide that we have previously shown could increase insulin mRNA and total insulin content in insulinoma cells. We infused 1.5 pmol/ kg 2 1 ·min 2 1 GLP-1 subcutaneously using ALZET ...
متن کاملGlucagon-Like Peptide-1
Ma Glucagon-like peptide-1-(7-36) amide (GLP-1) is a human incretin hormone responsible for the release of insulin in response to food. Pre-clinical and human physiological studies have demonstrated cardioprotection from ischemia-reperfusion injury. It can reduce infarct size, ischemic left ventricular dysfunction, and myocardial stunning. GLP-1 receptor agonists have also been shown to reduce ...
متن کاملGlucagon-like peptide-1 is a physiological incretin in rat.
Glucagon-like peptide-1 7-36 amide (GLP-1) has been postulated to be the primary hormonal mediator of the entero-insular axis but evidence has been indirect. The discovery of exendin (9-39), a GLP-1 receptor antagonist, allowed this to be further investigated. The IC50 for GLP-1 receptor binding, using RIN 5AH beta-cell membranes, was found to be 0.36 nmol/l for GLP-1 and 3.44 nmol/l for exendi...
متن کاملGLUCAGON-LIKE PEPTIDE 1: BIOChEMISTRy, SECRETION AND MAIN PhySIOLOGICAL EFFECTS
the peptide hormone glucagon-like peptide 1 (glp-1), produced in the intestinal l-cells by differential processing of proglucagon, is secreted in response to meal intake. glp-1 affects various systems, the gastrointestinal and pancreatic systems being the best studied, either by direct binding to the glp-1 receptor, at the target-cells surface, or indirectly as a result of paracrine regulation....
متن کاملAn overview of glucagon-like peptide-1 receptor agonists for the treatment of metabolic syndrome: A drug repositioning
Metabolic syndrome (MetS) is a clustering of several cardiovascular risk factors that include: obesity, dyslipidemia, hypertension and high blood glucose, and often requires multidrug pharmacological interventions. The management of MetS therefore requires high healthcare cost, and can result in poor drug treatment compliance. Hence drug therapies that have pleiotropic beneficial effects may be...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Scientific Reports
سال: 2017
ISSN: 2045-2322
DOI: 10.1038/s41598-017-12290-x